SCHEDULE: Citadel Discloses 3.2% Stake in BridgeBio Oncology
Beneficial Ownership Disclosure
Citadel entities and Kenneth Griffin report a 3.2% beneficial ownership in BridgeBio Oncology Therapeutics, Inc. Class A ordinary shares.
Summary
- Citadel Advisors LLC, Citadel Advisors Holdings LP, Citadel GP LLC, Citadel Securities LLC, Citadel Securities Group LP, Citadel Securities GP LLC, and Kenneth Griffin (collectively, the "Reporting Persons") have filed an Amendment No. 1 to Schedule 13G.
- The filing reports beneficial ownership of Class A ordinary shares of BridgeBio Oncology Therapeutics, Inc.
- As of September 30, 2025, Kenneth Griffin beneficially owns 2,538,142 shares, representing 3.2% of the outstanding Class A ordinary shares.
- Citadel Advisors LLC, Citadel Advisors Holdings LP, and Citadel GP LLC each beneficially own 2,528,762 shares, also representing 3.2% of the class.
- Citadel Securities LLC, Citadel Securities Group LP, and Citadel Securities GP LLC each beneficially own 9,380 shares, representing 0.0% of the class.
- The percentages are based on 79,196,710 shares outstanding as of immediately following the issuer's public offering on September 10, 2025.
- The Reporting Persons certify that the securities were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer.
Sentiment
Score: 5
Explanation: Neutral, as this is a factual disclosure of a passive ownership stake, not containing performance or strategic updates.
Future Outlook
NA
Industry Context
NA
Key Dates
| Date | Description |
|---|---|
| 2023-10-13 | Date of power of attorney filing by Citadel Advisors LLC for Allakos Inc., referenced for Kenneth Griffin's signature. |
| 2025-09-10 | Date of BridgeBio Oncology Therapeutics, Inc.'s public offering, used to calculate outstanding shares. |
| 2025-09-30 | Date of event requiring the filing of this statement. |
| 2025-11-14 | Filing date of this Schedule 13G Amendment No. 1. |
Keywords
BridgeBio Oncology Therapeutics, Citadel, Kenneth Griffin, Schedule 13G, Class A ordinary share, beneficial ownership, institutional investment, equity stake
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.